Roche's TIG­IT win lim­it­ed by stan­dard of care change, lack of glob­al study

Roche’s TIG­IT an­ti­body tiragolum­ab fi­nal­ly scored a Phase III win fol­low­ing two con­sec­u­tive late-stage fails last year, thanks to its SKY­SCRAPER-08 tri­al com­par­ing its TIG­IT against place­bo and chemother­a­py. But the com­par­i­son arm may leave some ques­tions unan­swered.

The da­ta, re­leased in an ab­stract as part of the 2024 AS­CO Gas­troin­testi­nal Can­cers Sym­po­sium, showed that tiragolum­ab in com­bi­na­tion with Roche’s oth­er check­point in­hibitor Tecen­triq, and chemother­a­py, met both pri­ma­ry end­points of pro­gres­sion-free sur­vival and over­all sur­vival with “sta­tis­ti­cal­ly sig­nif­i­cant” re­sults.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER